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Background:  Patient-specific epidemiologic ICP thresholds in adult TBI have emerged, using the 121 
relationship between pressure reactivity index (PRx) and ICP, displaying stronger association with 122 
outcome over existing guideline thresholds.  The goal of this study was to explore this relationship in a 123 
multi-center cohort in order to confirm the previous finding. 124 
Methods: Using the Collaborative European Neuro Trauma Effectiveness Research in TBI (CENTER-TBI) 125 
high-resolution intensive care unit (ICU) cohort, we derived individualized epidemiologic ICP thresholds 126 
for each patient using the relationship between PRx and ICP.  Mean hourly dose of ICP was calculated 127 
for every patient for the following thresholds:  20 mm Hg, 22 mm Hg and the patient’s individual ICP 128 
threshold. Univariate logistic regression models were created comparing mean hourly dose of ICP above 129 
thresholds to dichotomized outcome at 6 to 12-months, based on Glasgow Outcome Score – Extended 130 
(GOSE) (alive/dead - GOSE >=2/GOSE=1; favourable/unfavourable – GOSE 5 to 8/GOSE 1 to 4, 131 
respectively).  132 
Results: Individual threshold were identified in 65.3% of patients (n=128), in keeping with previous 133 
results (23.0 +/- 11.8 mm Hg (IQR: 14.9 to 29.8 mm Hg)). Mean hourly dose of ICP above individual 134 
threshold provides superior discrimination (AUC 0.678, p=0.029), over mean hourly dose above 20 mm 135 
Hg (AUC = 0.509, p=0.03) or above 22 mm Hg (AUC = 0.492, p=0.035) on univariate analysis for 136 
alive/dead outcome at 6 to 12 months. The AUC for mean hourly dose above individual threshold trends 137 
to higher values for favourable/unfavourable outcome, but fails to reach significance (AUC = 0.610, 138 
p=0.060). This was maintained when controlling for baseline admission characteristics. 139 
Conclusions: Mean hourly dose of ICP above individual epidemiologic ICP threshold has stronger 140 
associations with mortality compared to the dose above BTF defined thresholds of 20 or 22 mm Hg, 141 
confirming prior findings. Further studies on patient specific epidemiologic ICP thresholds are required. 142 
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Recent analysis of cerebral physiology in adult TBI has suggested a potential role of individualized 150 
treatment regimens based on advanced monitoring of cerebrovascular reactivity and the derivation of 151 
individualized cerebral perfusion pressure (CPP) targets, termed optimal CPP (CPPopt).[1,2] This 152 
represents a shift towards more individualized medicine in the care for moderate/severe TBI patients. 153 
Data from initial studies suggests stronger outcome associations with individualized CPP targets, 154 
compared to applying the same target range applied to all patients.[1–3]   155 
Aside from individualized CPP targets, individualized epidemiologic intracranial pressure (ICP) thresholds 156 
have been suggested based on a single center retrospective study in adult TBI.[4–6]  Using the 157 
relationship between continuously monitored cerebrovascular reactivity, using the pressure reactivity 158 
index (PRx), and ICP, one can find the ICP threshold where all subsequent higher ICP values yield PRx 159 
measures consistently above +0.20,[4] a threshold value for PRx known to be associated with impaired 160 
cerebrovascular reactivity and global outcome in adult TBI.[7–10] This has been termed the patient-161 
specific or individualized ICP threshold, identifiable in approximately 68% of patients.[4]  Prior 162 
retrospective analysis supports a potentially stronger association between the dose of ICP above 163 
individual epidemiologic thresholds, compared to the Brain Trauma Foundation (BTF) guideline defined 164 
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threshold of 20 mm Hg, with global outcome in TBI.[4]  However, this has not been replicated in any 165 
other group of patients or outside of this single center.   166 
The goal of this study is to utilize the multi-center Collaborative European Neuro Trauma Effectiveness 167 
Research in TBI (CENTER-TBI) study[11] high-resolution intensive care unit (ICU) cohort data set, to 168 
evaluate the ability to derive individualized ICP epidemiological thresholds using a semi-automated 169 
algorithm and compare the association between dose above individual threshold and BTF guideline ICP 170 
thresholds (ie. 20 mmHg and 22 mmHg) with global patient outcome. 171 
 172 
Methods: 173 
Patient Population: 174 
All patients from the multi-center CENTER-TBI high resolution ICU cohort were included in this study.  175 
These patients were prospectively recruited during the periods of January 2015 to December 2017. A 176 
total of 21 centers in the European Union (EU) contributed. All patients were admitted to ICU for their 177 
TBI during the course of the study, with high frequency digital signals recorded from their ICU monitors 178 
during the course of their ICU stay.  All patients suffered predominantly from moderate to severe TBI 179 
(moderate = Glasgow Coma Score (GCS) 9 to 12, and severe = GCS of 8 or less).  A minority of patients 180 
suffered from mild TBI (GCS13-15), with subsequent early deterioration leading to ICU admission for 181 
care and monitoring.  All patients in this cohort had invasive ICP monitoring conducted in accordance 182 
with the BTF guidelines.[12]   183 
 184 
Ethics: Data used in these analyses were collected as part of the CENTER-TBI study which had individual 185 
national or local regulatory approval; the UK Ethics approval is provided as an exemplar: IRAS No: 186 
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150943; REC 14/SC/1370).  The CENTER-TBI study (EC grant 602150) has been conducted in accordance 187 
with all relevant laws of the EU if directly applicable or of direct effect and all relevant laws of the 188 
country where the Recruiting sites were located, including but not limited to, the relevant privacy and 189 
data protection laws and regulations (the “Privacy Law”), the relevant laws and regulations on the use of 190 
human materials, and all relevant guidance relating to clinical studies from time to time in force 191 
including, but not limited to, the ICH Harmonised Tripartite Guideline for Good Clinical Practice 192 
(CPMP/ICH/135/95) (“ICH GCP”) and the World Medical Association Declaration of Helsinki entitled 193 
“Ethical Principles for Medical Research Involving Human Subjects”. Informed Consent by the patients 194 
and/or the legal representative/next of kin was obtained, accordingly to the local legislations, for all 195 
patients recruited in the Core Dataset of CENTER-TBI and documented in the e-CRF. 196 
Data Collection: 197 
As part of recruitment to the multi-center high resolution ICU cohort of CENTER-TBI,[11] all patients had 198 
demographics prospectively recorded.  Similarly, all patients had high frequency digital signals from ICU 199 
monitoring recorded throughout their ICU stay, with the goal of initiating recording within 24 hours of 200 
ICU admission.  All digital ICU signals were further processed (see Signal Acquisition/Signal Processing). 201 
For the purpose of this study, the following admission demographic variables were collected:  age, sex, 202 
admission Glasgow Coma Scale (GCS – total and motor) and admission pupillary response (bilaterally 203 
reactive, unilateral reactive, bilateral unreactive). We focused on the use of entirely non-imputed raw 204 
data, as final imputation of the entire CENTER-TBI dataset is an ongoing process and will be part of 205 
subsequent publications and analysis. CENTER-TBI data was accessed/extracted using Opal database 206 
software[13], accessed on Sept 16th, 2018. 207 
 208 
Signal Acquisition and Processing: 209 
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Signal acquisition and processing was conducted in an identical manner to previous CENTER-TBI high 210 
resolution ICU sub-study publications.  Details can be found in Appendix A and the previous publications 211 
from this cohort.[14,15] PRx was derived via the moving correlation coefficient between 30 consecutive 212 
10 second mean windows of the parent signals (ICP and mean arterial pressure (MAP)), updated every 213 
minute.[16] 214 
 215 
Individual Patient Specific ICP Threshold Determination 216 
For each patient, the relationship between PRx and ICP for the entire recording period was utilized to 217 
determine their individual ICP epidemiologic threshold.  Based on the methodology outlined in the 218 
previous publications on the topic,[4] the ICP value where PRx is +0.20, and all higher ICP values have 219 
PRx values persistently above +0.20 was considered the individual ICP threshold.  Previous publications 220 
employed manual direct observation of the relationship between PRx and ICP, via error bar plotting, to 221 
determine the individual ICP threshold.[4,5] It must be acknowledged that these individual thresholds 222 
for ICP do not represent therapeutic targets, but an individualized epidemiological thresholds, derived 223 
from the relationship between cerebrovascular reactivity values associated with global long-term 224 
outcome. Thus the derived individual thresholds quoted within the manuscript should not be considered 225 
as therapeutic in nature, and purely preliminary exploratory work into personalized ICP thresholds in 226 
TBI. Further, the method for determination requires the use of the entire recording period, limiting this 227 
current technique to purely retrospective analysis. 228 
In this study, we developed a semi-automated algorithmic method using R statistical computing 229 
software (R Core Team (2016). R: A language and environment for statistical computing. R Foundation 230 
for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).  First, for every patient an 231 
error bar plot of PRx vs. ICP, using 2.5 mm Hg bins of ICP, was constructed for each patient.  This was 232 
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smoothed using locally weighted scatterplot smoothing (LOESS) functions for each patient. Second, 233 
using these LOESS fitted values, we subsequently identified the lowest ICP value for which PRx was 234 
between +0.19 and +0.21 (ie. the lowest ICP values for intersection between the fitted LOESS function 235 
and the line “y” = +0.20 (ie. PRx = +0.20). This ICP value was selected as the patient’s individual ICP 236 
threshold.  These thresholds were then assessed for validity by manual inspection of each patient’s error 237 
bar and LOESS function plots of PRx versus ICP.  Any discrepancies between the algorithm-derived 238 
individual ICP threshold and the manually inspected ICP threshold were then corrected by hand, if 239 
present (hence “semi-automated”).  Figure 1 displays two patient examples of the error bar and LOESS 240 
function plots, with the individual ICP threshold identification. 241 
 242 
*Figure 1 here 243 
 244 
 245 
Data Processing: 246 
Grand mean values of all physiologic variables were calculated per patient.  In addition, post-ICM+ 247 
processing of physiologic data occurred in R. Dose above ICP threshold was determined for the BTF 248 
defined ICP thresholds of 20 mm Hg and 22 mm Hg, as well as for the patient’s individual ICP threshold.  249 
Dose was calculated in the following manner for each min-by-min observation:  if ICP > ICP Threshold, 250 
then Dose = ICP – ICP Threshold, otherwise generate no value.  We then summated the dose over the 251 
entire recording period, and subsequently divided this value by the total duration of recording (in hours) 252 
to generate the mean hourly dose above threshold for thresholds of: 20 mm Hg, 22 mm Hg and the 253 






All statistical analysis was conducted using R (R Core Team (2016). R: A language and environment for 258 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-259 
project.org/) and XLSTAT (Addinsoft, New York, NY; https://www.xlstat.com/en/) add-on package to 260 
Microsoft Excel (Microsoft Office 15, Version 16.0.7369.1323).  Normality of continuous variables was 261 
assessed via Shapiro-Wilks test.  For all testing described within, the alpha was set at 0.05 for 262 
significance. All continuous variables were found to be non-parametrically distributed. 263 
Despite GOSE being collected at both 6- and 12-months post-injury in this cohort of patients, there was 264 
missing data present in both categories of outcome, as described in previous publications from the 265 
CENTER-TBI high-resolution ICU cohort.  Thus, we combined GOSE scores from both 6 and 12 months in 266 
order to provide a “6 to 12 Month” GOSE.  For patients where GOSE was reported for both 6 and 12 267 
months, the last (ie. latest or 12 month) GOSE score was selected for analysis.   268 
GOSE was then dichotomized into the following categories:  A. Alive (GOSE 2 to 8) vs. Dead (GOSE 1); 269 
and B. Favourable (GOSE 5 to 8) vs. Unfavourable (GOSE 4 or less).  Demographics and physiologic 270 
variables were compared between each dichotomized group using: Mann-Whitney U and chi-square 271 
testing where appropriate.  Box plots were created for variables of interest comparing between 272 
dichotomized groups. 273 
Univariate logistic regression (ULR) and bivariate logistic regression was conducted, comparing variables 274 
to both dichotomized GOSE outcomes, assessing superiority via AUC, Akaike Information Criterion (AIC) 275 
and Delong’s Test. Only ULR and bivariate logistic regression was conducted as this is only the second 276 
set of data for which individual ICP thresholds have been assessed, and we were only interested in 277 
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testing a new algorithm for detection and validate the previous single-center results.  Bivariate models 278 
composed of hourly dose above ICP of 20 mm Hg and mean PRx, and hourly dose above ICP of 22 mm 279 
Hg and mean PRx, were both created to assess association with both dichotomized outcomes. These 280 
models were compare to the univariate models which assessed the association between hourly dose 281 
above individual ICP threshold and the dichotomized outcomes.  282 
Finally, the results from the univariate logistic regression analysis were confirmed through multi-variable 283 
logistic regression, by controlling for standard International Mission for Prognosis and Analysis of Clinical 284 
Trials in TBI Core (IMPACT-Core) admission variables:  age, GCS motor sub-score and pupillary response 285 
(as measured through an ordinal scale:  bilaterally reactive, unilateral reactive, bilateral unreactive).[17]  286 
Note, not all patients had a complete data set for this analysis, and so we focused only on those with 287 
complete IMPACT-Core variables and identifiable individual ICP thresholds (ie. n=127). 288 
 289 
Results: 290 
Patient Demographics 291 
There were 196 patients from the CENTER-TBI high-resolution ICU cohort, with high-frequency 292 
physiologic signals and demographic variables, which were included in this study. This particular cohort 293 
has been described in detail within previous publications.[14]  The mean age was 46.6 +/- 19.7 years, 294 
with 150 being male.  Median admission GCS was 8 (IQR: 5 to 13), and mean duration of physiologic 295 
monitoring was 159.3 +/- 115.1 hours.  296 
Using the semi-automated algorithm described to determine individual ICP thresholds, a total of 128 out 297 
of 196 (65.3%) had an identifiable individual ICP epidemiologic threshold, in keeping with previous single 298 
center literature on the topic,[4] with mean individual ICP threshold of 23.0 +/- 11.8 mm Hg (IQR: 14.9 to 299 
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29.8 mm Hg), and 73 of the 128 patients with an identifiable individual ICP threshold displaying 300 
individual thresholds above BTF defined 20 mm Hg.  Our semi-automated algorithm correctly identified 301 
the presence or absence of a patient’s individual ICP threshold in 162 out of 196 (83.2%).  Thirty-four 302 
patients had either an incorrectly identified individual ICP threshold when there wasn’t one present 303 
(n=20), or no individual ICP threshold identified when there was one present (n=14).  These 34 304 
discrepancies were identified through manual inspection of both the error bar and LOESS function plots 305 
of PRx versus ICP, and subsequently corrected. 306 
Patient demographics for those patients with an individual ICP threshold and those without an 307 
identifiable individual ICP threshold can be seen in Table 1, with comparison of demographic and 308 
physiologic factors between the two groups of patients.  Of note is the higher mean ICP (p=0.041) and 309 
PRx (p<0.0001) in the patients without an identifiable individual ICP threshold, as identified via Mann-310 
Whitney U testing, with a sustained higher PRx value in keeping without being able to identify an ICP 311 
threshold using the described methodology.  312 
 313 
*Table 1 here 314 
 315 
Comparing demographics and physiologic variables between dichotomized outcome groups for the 316 
patents with an identifiable individual ICP threshold, we find that only mean PRx (p<0.001 for 317 
alive/dead, and p=0.005 for favourable/unfavourable outcomes) and mean hourly dose above the 318 
patient’s individual ICP threshold (p=0.010 for alive/dead, and p=0.020 for favourable/unfavourable 319 
outcomes) are significantly different (ie. higher), via Mann-Whitney U testing, in those who died or 320 
demonstrated unfavourable outcome at 6 to 12-months.  Mean hourly dose of ICP above 20 and 22 mm 321 
Hg failed to display any significant difference between the dichotomized groups.  Appendix B provides a 322 
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tabulated summary of this information. Figure 2 displays box plots of the mean hourly dose above each 323 
ICP threshold across both dichotomized outcomes. 324 
 325 







Mean Hourly Dose of ICP Above Threshold and Outcome – Univariate Analysis 333 
Univariate logistic regression was performed for each demographic and mean hourly dose of ICP above 334 
threshold with both 6 to 12-month dichotomized outcomes.  Table 2 displays the results of the ULR 335 
analysis with AUC’s, AIC and p-values tabulated for each variable. Age was noted to be statistically 336 
associated with both alive/dead (AUC = 0.820; 95% CI 0.736-0.904; p<0.0001) and 337 
favourable/unfavourable (AUC = 0.708; 95% CI 0.618-0.799; p<0.0001) outcomes.  Higher mean PRx was 338 
also noted to be associated with mortality and unfavorable outcome, in keeping with the previous larger 339 
single-center studies on cerebrovascular reactivity in adult TBI.[7,10,16]  340 
The mean hourly dose of ICP above the patient’s individual threshold displayed the highest AUC’s and 341 
lowest AIC values for association with both dichotomized outcomes (AUC = 0.678, p=0.029 for 342 
alive/dead, and AUC = 0.610, p=0.060 for favourable/unfavourable), with higher dose associated with 343 
mortality and unfavourable 6 to 12-month outcome. This was in comparison to the mean hourly dose of 344 
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ICP above the BTF based treatment thresholds of 20 and 22 mm Hg,[12] as well as bivariate models 345 
including mean hourly ICP dose above 20/22 mm Hg and mean PRx. The association with mortality was 346 
statistically much stronger than unfavourable outcome, also in keeping with previous studies assessing 347 
the association between ICP and global outcome in adult TBI.[7,12]  348 
 349 
*Table 2 here 350 
 351 
 352 
Comparing AUC’s via Delong’s test indicated that there was a significant difference between the AUC for 353 
mean hourly dose of ICP above individual threshold and both mean hourly dose of ICP above 20 and 22 354 
mm Hg for alive/dead outcome (p=0.047 and p=0.044, respectively).  However, no significant difference 355 
was noted between the AUC’s of the three hourly dosing variables when outcomes where dichotomized 356 
as favourable/unfavourable.  357 
Finally, Comparing the bivariate models with mean hourly dose of ICP above 20/22 mm Hg and mean 358 
PRx, to the univariate model with mean hourly dose of ICP above individual threshold, for alive/dead 359 
outcome, the univariate models with mean hourly dose of ICP above individual threshold displayed 360 
statistically significant higher AUC’s compared to the bivariate models (p<0.05 for all; Delong’s test). 361 
There was no difference in AUC when comparing the bivariate models to the univariate individual 362 
threshold model for favorable/unfavourable outcome. Figure 3 displays the univariate receiver 363 
operating curves for mean hourly dose of ICP above 20 mm Hg, above 22 mm Hg, and above individual 364 
ICP threshold.  365 
 366 






Controlling for Admission IMPACT-Core Variables 371 
Only 127 of the 128 patients with identifiable individual ICP thresholds had complete IMPACT-Core 372 
admission variables.  Controlling for these admission characteristics in multi-variable logistic regression, 373 
it was found that comparing models with baseline characteristics and mean hourly dose of ICP above 20 374 
mmHg or 22 mmHg, to those with mean hourly dose above individual ICP threshold, that the models 375 
with mean hourly dose above individual threshold trended toward higher statistically significant AUC’s, 376 
for both dichotomized outcomes. This confirms that the mean hourly dose above individual ICP 377 
threshold maintains significance, when controlling for IMPACT-Core covariates.  Appendix C provides a 378 
table summarizing the findings for the multi-variable logistic regression analysis. 379 
 380 
Discussion: 381 
This validation study provides multi-center confirmation of the presence of individual epidemiologic ICP 382 
thresholds, and replicates the strong association between time spent above this threshold and global 383 
outcome in adult TBI. There are some important aspects which deserve highlighting. 384 
First, we have been able to display that individual ICP thresholds in moderate/severe TBI can be 385 
detected in 65.3% of patients from this cohort.  This is in keeping with prior retrospective single center 386 
results on the topic.[4]  This is an important finding because not only does it validate previous results, 387 
but it also suggests that future studies will need to take this into account in order to be powered 388 
appropriately. Failure to detect individual threshold may be attributed to low ICP (never disturbing 389 
autoregulation) or too high ICP, when autoregulation is continuously disturbed. The wide distribution of 390 
individualized thresholds (interquartile range) from 14.9 to 29.8 mm Hg underlines the importance of 391 
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such approaches to examining the individually defined burden of intracranial hypertension, as opposed 392 
to accepting fixed thresholds that are identical across patients. The individual thresholds identified for 393 
ICP below the BTF guideline ICP thresholds of 20 or 22 mm Hg are at this point still unclear in 394 
significance.  This methodology is still very much nascent, with this current work only being the second 395 
in the literature, and requires substantial validation and exploration in other TBI populations as well as 396 
controlled experimental models.  Thus, these ICP thresholds below 20 mm Hg require further 397 
investigation, and we in no way suggest that ICP targets would be changed to target such low values.  398 
There needs to be a substantial subpopulation analysis in those patients who display low individual ICP 399 
thresholds, in order to explain why such values may exist.  This will be the focus of future studies on the 400 
topic. As mentioned, the goal of this study was to only provide a multi-center validation of the 401 
previously published single-center retrospective results from Cambridge.[4] 402 
Second, we have, for the first time, created a semi-automated algorithm for the detection of individual 403 
ICP thresholds, an improvement over prior completely manual determination from plots of PRx and ICP.  404 
Though a first attempt, the accuracy rate in this study was 83.2%.  It must be acknowledged that the 405 
notion of using an abnormal ICP compliance curve doesn’t require a computer to determine, and can in 406 
fact be determined by inspection of the plotted physiology at the bedside by the treating clinician. Thus, 407 
our semi-automated algorithmic process would benefit from refinement and optimization, which will be 408 
the focus of future analyses in this area.  Further to this, there are other potential options for assessing 409 
individual patient ICP thresholds, employing cerebral compliance indices, such as RAP (correlation 410 
between pulse amplitude of ICP and ICP),[18,19] or using ICP waveform analytic techniques.[20,21] 411 
Exploration into these techniques as means to derive individual ICP thresholds is required, but may 412 
prove fruitful.  413 
Third, we have been able to confirm the strong association between and dose of ICP above individual 414 
ICP threshold, which was shown in the original publication describing this relationship,(6) and done so in 415 
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a multi-center data set. These results validate the presence and detectability of individual ICP 416 
thresholds, and provide a conceptual framework for developing these as treatment targets in the future 417 
targets, as we move towards individualized medicine. Support for such an approach is justified in the 418 
stronger association between mean hourly dose of ICP above individual threshold and both 419 
dichotomized 6 to 12-month outcomes, using ULR and multi-variable logistic regression controlling for 420 
standard IMPACT-Core admission characteristics. ICP (time x intensity) dose calculated above individual 421 
thresholds were much more strongly associated with outcome compared to the dose above BTF defined 422 
thresholds of 20 and 22 mm Hg.[12].   The current analysis focuses on confirmation of past findings, but 423 
subsequent work will examine the impact of individual ICP thresholds in more complex multi-variable 424 
models which include co-variates beyond those used in the IMPACT-Core prediction model.   425 
Thus, there is still limited data to support the adoption of individual ICP thresholds as a clinically utilized 426 
measure at this time. 427 
Fourth, an important finding re-iterated by the results of this work is that ICP and burden of ICP suffered 428 
after TBI is linked to outcome in TBI.  Particularly the dose of ICP spent above BTF thresholds, as well as 429 
individual ICP threshold, was statistically significantly associated with outcome.  This is important to 430 
emphasize as recent literature has led to questions regarding the utility of ICP monitoring in adult 431 
TBI,[22,23] leading to confusion in some providers as to the need for such monitoring devices. However, 432 
the results within this work added to the existing large body of evidence supporting the link between ICP 433 
and patient outcome in TBI.[7,12,24] 434 
One shortcoming of the approach implemented in this manuscript is that individualized thresholds were 435 
calculated based on all of the ICP values across the patient stay. This approach clearly does not lend 436 
itself to providing a management target early in the course of the patient’s stay, which is when it is 437 
needed.  However, the we hypothesize that individual thresholds of ICP may be detectable on-line (on 438 
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the basis of recent ICP monitoring data points), and provide decision support for individualized 439 
management across all tiers of ICP therapy- starting from hypertonic solutions and finishing with better 440 
targeted decompressive craniectomy. Such a concept is still experimental and would require the use of 441 
sliding windows of data over time, to calculate the intersect between the PRx versus ICP function and 442 
PRx of +0.20. We envision such methodology to be similar to current CPP optimum sliding window 443 
determinations employed in real-time.[1–3]  However, it should be acknowledged that the feasibility of 444 
this has not been tested, and the concept is only a theory requiring much further investigation. If proven 445 
feasible, this would allow for a continuously updating individual ICP threshold value which could then 446 
account for changes in individual thresholds over time, where the current described methodology is 447 
incapable of accomplishing.  448 
 449 
Limitations 450 
Important limitations deserve highlighting.  First, as mentioned in other studies published from this 451 
cohort,[14] despite the data from the CENTER-TBI high-resolution cohort being collected in a 452 
prospective manner, the treatments and therapies received by patients remain heterogeneous. Such 453 
heterogeneity may have impacted the individual ICP threshold determination, and it is currently unclear 454 
whether individual therapeutic measures directed at ICP differentially impact the derivation of 455 
individualized thresholds.  Such analysis, including the impact of injury and patient heterogeneity, will 456 
require even larger prospectively collected high-resolution data sets.   457 
Second, our methodology for identification of individual ICP thresholds relies on the use of PRx, as 458 
previously described.[4] This current study was conduct as a simple validation of this previous 459 
retrospective single-center work.  However, given the methodology of individual ICP thresholds is still 460 
new, there is the potential that other methods for estimating such thresholds may prove equivalent or 461 
superior.  There is the potential that thresholding ICP based on autoregulation may be too simplistic, 462 
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and other measures, such as compensatory reserve metrics,[18,19] may provide more information 463 
regarding stratifying critical values of ICP.  The concept of individual ICP thresholds using PRx is still in its 464 
experimental. This concept is based on individual ICP thresholds derived through impairment in 465 
cerebrovascular reactivity, through epidemiologically defined critical values from previous retrospective 466 
studies,[7] not compensatory reserve.  It still remains unclear if using a pure compliance/compensatory 467 
reserve index such as RAP,[18,19] would provide different information for the determination of 468 
individual ICP thresholds. Cerebrovascular reactivity can be impaired in both settings of normal and 469 
elevated ICP in adult TBI, where compensatory reserve indices tend to remain normal until extreme ICP 470 
elevations. Hence, we decided to employ a method of individual ICP threshold determination using 471 
vascular reactivity. It is unclear if these calculated thresholds occurring at lower ICP values represent 472 
normal brain or just dysautoregulation and pressure-passivity at low ICP.  Further work is required to 473 
correlate these findings with other continuously derived cerebral physiologic metrics (such as blood flow 474 
velocity, PbtO2, CBF, or near-infrared based measures) and neuroimaging biomarkers, in order to 475 
determine is the brain is in a “normal” state when individual ICP thresholds are determined to be below 476 
20 mm Hg.  As such, the current methodology should be considered an experimental starting point for 477 
such analysis, and not employed in the treatment of patients.  There are plans for much further analysis 478 
of other physiologic metrics for the derivation of individual ICP thresholds, and these will for the focus of 479 
various other studies on both the Cambridge retrospective TBI database and the CENTER-TBI high 480 
resolution ICU cohort.   481 
Third, the overall patient numbers with an identifiable individual ICP threshold was low, at 128 and only 482 
127 with full IMPACT-Core admission variables and an identifiable individual ICP threshold.  Though 483 
based on the initial population size with a documented outcome and presence of baseline 484 
characteristics (n=196), a yield of 65.3% for individual ICP threshold is in keeping with prior larger 485 
retrospective studies on the topic.[4]  This relatively small population effect may be exemplified by the 486 
20 
 
low AUC values on univariate analysis, and during correction for baseline IMPACT-Core co-variates, 487 
despite reaching statistical significance. As such, future investigations into individualized ICP thresholds 488 
will definitely require larger cohorts.  At the moment, we are unable to make definitive comments on 489 
the characteristics related to not being able to derive an individual ICP threshold.  It is possible that 490 
patient admission demographics and both extra- and intra-cranial injury burden characteristics will be 491 
predictive of those patients in whom an individual ICP is not identifiable.  Such analysis was not the 492 
focus of this study, and will form the basis for a much larger analysis conducted on an amalgamated 493 
cohort from the large retrospective Cambridge TBI database and the CENTER-TBI high resolution ICU 494 
cohort. The hope is with such larger patient cohorts, we will be able to shed some light on the topic. 495 
Fourth, despite the automated portion of the algorithm for detection of individualized ICP thresholds 496 
demonstrating an acceptable accuracy rate of 83.2%, there still existing substantial room for 497 
improvement.  As this was the first attempt at producing an semi-automated approach for individual ICP 498 
threshold determination, we feel encouraged about being able to improve upon this, as previous 499 
methods required a completely manual inspection of plots.[4] This will be the focus of future work. 500 
Fifth, despite our results indicating that those patients with no discernable individual ICP threshold 501 
displayed higher mean PRx and ICP values, our understanding as to the characteristics of such patients is 502 
limited.  Future analysis of individual ICP thresholds will not only need to focus on those with an 503 
identifiable threshold, but also on those without, so we can better understand what contributes to a 504 
lack of a patient-specific threshold.  505 
Finally, despite the finding that ICP doses derived from individualized ICP thresholds display potentially 506 
stronger associations with outcome compared to BTF defined thresholds, the concept of individualized 507 
threshold should still be considered experimental.  Currently, individual ICP thresholds should not 508 
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replace the BTF defined thresholds in monitoring and care of moderate and severe TBI patients. Much 509 
further evidence is required to validate these individualized targets as clinically valuable in TBI. 510 
 511 
Conclusions: 512 
Individual epidemiologic ICP thresholds are present in two thirds of the adult TBI population.  Mean 513 
hourly dose of ICP above a patient’s individual epidemiologic ICP threshold demonstrates a stronger 514 
association with mortality compared to the dose above BTF defined thresholds of 20 or 22 mm Hg, 515 
confirming prior single center findings. Further studies on individual patient specific epidemiologic ICP 516 
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Figure Legends: 672 
Figure 1: Two Patient Examples of Individual ICP Threshold Determination via Semi-Automated Method 673 
a.u. = arbitrary units, ICP = intracranial pressure, LOESS = locally weighted scatterplot smoothing, mm Hg = millimeters of 674 
Mercury, MAP = mean arterial blood pressure, PRx = pressure reactivity index (correlation between ICP and MAP). Panel A and B 675 
= patient 1, Panel C and D = patient 2. Panel A – error bar plot of PRx vs. ICP, dotted line displays PRx threshold of +0.20, Panel B 676 
– LOESS function plot with 95% confidence intervals, intersection between PRx = +0.20 line (dotted) and the LOESS function 677 
yields the patients individual ICP threshold.  Panels C and D display similar finding for a second patient.  678 
 679 
Figure 2: Box Plots of Mean Hourly Dose Above ICP Threshold for Dichotomized 6 to 12-Month Outcome Groups 680 
GOSE = Glasgow Outcome Score – Extended, ICP = intracranial pressure, mm Hg = millimeters of Mercury.  Panel A – Mean 681 
hourly hose of ICP above 20 mm Hg  for alive and dead (A/D) outcome, Panel B – Mean hourly hose of ICP above 20 mm Hg for 682 
favourable and unfavourable (F/U) outcome, Panel C – Mean hourly hose of ICP above 22 mm Hg for alive and dead (A/D) 683 
outcome, Panel D – Mean hourly hose of ICP above 22 mm Hg for favourable and unfavourable (F/U) outcome, Panel E – Mean 684 
hourly dose of ICP above patient’s individual ICP threshold for alive/dead (A/D) outcome, Panel F – Mean hourly dose of ICP 685 
above patient’s individual ICP threshold for favourable/unfavourable (F/U) outcome. Alive/Dead (A/D) Dichotomization (Alive = 686 
GOSE >=2, Dead = GOSE 1). Favourable/Unfavourable (F/U) Dichotomization (Favourable = GOSE 5 to 8, Unfavourable = GOSE 1 687 
to 4). *p-values reported are for Mann-Whitney-U test, comparing mean values between dichotomized groupings. 688 
 689 
Figure 3: Univariate Logistic Regression – Mean Hourly Dose of ICP Above 20, 22 and Individual Thresholds 690 
GOSE = Glasgow Outcome Scale Extended, ICP = intracranial pressure, ULR = Univariate Logistic Regression. Panel A = Mean 691 
Hourly Dose of ICP Above 20 mm Hg ULR for Alive/Dead (A/D) Outcome, Panel B = Mean Hourly Dose of ICP Above 20 mm Hg 692 
ULR for Favourable/Unfavourable (F/U) Outcome, Panel C = Mean Hourly Dose of ICP Above 22 mm Hg ULR for Alive/Dead (A/D) 693 
Outcome, Panel D = Mean Hourly Dose of ICP Above 22 mm Hg for Favourable/Unfavourable (F/U) Outcome, Panel E = Mean 694 
Hourly Dose of ICP Above Individual Threshold ULR for Alive/Dead (A/D) Outcome, Panel F = Mean Hourly ICP Dose Above 695 
Individual Threshold ULR for Favourable/Unfavourable (F/U) Outcome. Alive/Dead (A/D) Dichotomization (Alive = GOSE >=2, 696 
Dead = GOSE 1). Favourable/Unfavourable (F/U) Dichotomization (Favourable = GOSE 5 to 8, Unfavourable = GOSE 1 to 4). 697 
*Indicates AUC reported failed to reach statistical significance in the ULR model. 698 
 699 
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